PENZBERG, Germany--(BUSINESS WIRE)--The xCELLigence RTCA System from Roche Applied Science allows for label-free, continuous monitoring of cell phenotypic changes using electrical impedance as readout. The interaction of cells with the electronic biosensors leads to the generation of a cell-electrode impedance response which indicates the status of the cells in terms of cell number, cell viability, cell morphology and cell attachment quality. Real-time, continuous measurement ensures the documentation of cell phenotypes in the form of time- dependent cell response profiles (TCRP).
In a recent study, the utility of the Roche xCELLigence System was explored for assessing RNAi-mediated knockdown of gene function. Researchers focused on Eg5, a kinesin involved in the mitosis pathway. Their results provide evidence that real-time cell monitoring using the xCELLigence System is ideal for identifying the optimal time point for further molecular and biochemical analyses of cellular events. The study showed that transfection of siRNA targeted to Eg5 produces a transient cell phenotype, with maximum expression at 27 hours post-transfection.
The real-time online aspect of the xCELLigence System has made it possible to directly link phenotypic cellular events to the molecular and biochemical changes that occur after transfection with siRNA. Conventional analysis of the data at time points before or after 27 hours post-transfection would have missed this optimal window of opportunity for carrying out relevant gene and protein expression assays. Furthermore, the real-time data stream of the xCELLigence System provides a continuous, label-free measure of cell culture quality control for transfection, simultaneously identifying potential off-target effects of the siRNA.
For more information please visit
https://www.roche-applied-science.com/sis/cellanalysis/cell_docs/CA-AppliNote04_Prod_LR.pdf
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
XCELLIGENCE is a trademark of Roche.
Other brands or product names are trademarks of their respective holders.
Contact:
Roche Diagnostics Dr. Burkhard Ziebolz Phone: +49 8856 604830 Email: burkhard.ziebolz@roche.com
